Advancing Pediatric Drug Development

Influence of pharmacogenomics on antiemetic response and efficacy

Briefly describe your research question :

Does CYP2D6 genotype influence ondansetron efficacy and/or toxicity?  For example, do patients with a CYP2D6 ultra-rapid metabolizer phenotype experience more treatment failure?  Do patients with intermediate or poor metabolizer phenotype experience greater toxicity (e.g., QT prolongation, headache, constipation).

https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/

Tags

Annotations

Voting

2 votes
Idea No. 166